EUVIMEDEUVIMED entdecken
Crossref

Tracking trends in the Top End: clindamycin and erythromycin resistance in Group A Streptococcus in the Northern Territory, 2012–2023

Joanne Nixon, Jann Hennessy, Rob W Baird

Communicable Diseases Intelligence · 2024

DOI: 10.33321/cdi.2024.48.31 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2024. Verfasst von Joanne Nixon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Trainee Infectious Diseases and Acute and General Care Medicine. Hauptthemen laut MEDLINE: Clindamycin, Erythromycin, Streptococcus pyogenes, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This retrospective study reviewed the macrolide resistance rates of Group A Streptococcus (GAS) isolates in the Northern Territory from 2012 to 2023. Clindamycin and erythromycin resistance rates peaked in 2021, at 6.0% and 12.2% respectively, and then returned to near baseline at 1–2% in 2023. Increased resistance rates were identified in the Top End of Australia from mid-2020, followed 15 months later by high rates in central Australia in 2022. Factors associated with resistant isolates were living in a rural region and of age 18 years and older. Possible explanations include a transient clonal introduction of a resistant GAS strain to the Northern Territory from 2020 to 2022. Ongoing surveillance is required to monitor regional trends and identify temporal variations in resistant isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClindamycinErythromycinStreptococcus pyogenesAnti-Bacterial AgentsStreptococcal InfectionsDrug Resistance, BacterialHumansNorthern TerritoryRetrospective StudiesFemaleAdultMaleAdolescentMiddle AgedChildYoung AdultChild, PreschoolAgedMicrobial Sensitivity TestsInfant

Stichwörter der Autor:innen

Group A streptococcusNorthern TerritoryStreptococcus pyogenesclindamycinerythromycinresistance

Substanzen

ClindamycinErythromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Advanced Trainee Infectious Diseases and Acute and General Care Medicine.
  • Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
  • Department of Microbiology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
  • Clinical Microbiologist and Director of Pathology, Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.

Zitieren

APA

Nixon, J., Hennessy, J., & Baird, R. W. (2024). Tracking trends in the Top End: clindamycin and erythromycin resistance in Group A Streptococcus in the Northern Territory, 2012–2023. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2024.48.31

Vancouver

Nixon J, Hennessy J, Baird RW. Tracking trends in the Top End: clindamycin and erythromycin resistance in Group A Streptococcus in the Northern Territory, 2012–2023. Communicable Diseases Intelligence. 2024. doi:10.33321/cdi.2024.48.31

BibTeX
@article{Nixon2024,
  author = {Nixon, Joanne and Hennessy, Jann and Baird, Rob W},
  title = {Tracking trends in the Top End: clindamycin and erythromycin resistance in Group A Streptococcus in the Northern Territory, 2012–2023},
  journal = {Communicable Diseases Intelligence},
  year = {2024},
  doi = {10.33321/cdi.2024.48.31}
}
Kostenlos starten →